NCT05994157 - Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions

Non-hodgkin Lymphoma

Interventions

DRUG

CD38-SADA:177Lu-DOTA Complex

The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.

Trial Locations (6)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Stony Brook Cancer Center, Stony Brook

NOT_YET_RECRUITING

East Carolina University Leo W. Jenkins Cancer Center, Greenville

RECRUITING

Corewell Health-BAMF Health, Grand Rapids

RECRUITING

HonorHealth, Scottsdale

RECRUITING

City of Hope, Duarte